Dp120 | a Nationwide Italian Survey on Tandem Autologous Stem-cell Transplantation for Newly Diagnosed Multiple Myeloma Treated With Daratumumab-bortezomib-thalidomide-dexamethasone Induction
Year: 2025
Type: article
Abstract: Quadruplet induction with D-VTd followed by single ASCT is the current standard treatment for NDMM in European Countries. However, in the latest EHA guidelines tandem ASCT is still recommended as an option for high-risk (HR) patients (pts), based on previous studies suggesting a survival benefit in this setting. On behalf of the GIMEMA Multiple Myeloma Working Party, we conducted a retrospective, multicenter, nationwide survey across 65 Italian centers on the use of tandem ASCT in NDMM pts from January 1st, 2022 to June 30th, 2024 (Table 1). The analysis of patients who actually received treatment are herein reported. During the study period, 2759 NDMM pts received D-VTd induction. Of these, 1106 (40.1%) pts had <60 years at diagnosis, 747 (27.1%) carried at least one HR FISH abnormality, including del17(p13), t(4;14), t(14;16), and gain/amp(1q21), and 686 (24.9%) pts had ISS 3 or R-ISS 3 disease stage. After D-VTd induction, 971 (35.2%) pts obtained ≥ CR. At data cut-off (January 9th, 2025), 1779 pts had received a single ASCT: of these, 647 (68.1%) in 2022, 744 (64.5%) in 2023, and 388 (59.1%) pts in the first six months of 2024. Over the same period, tandem ASCT was preplanned in 980 pts (35.6%) and was actually received in 741 of them: 257 (27.1%) pts in 2022, 346 (30%) in 2023, and 138 (21%) pts in the first six months of 2024. Across participating centers, the choice of tandem ASCT was based on multiple criteria, the most common being the presence at baseline of HR FISH abnormalities (86%), extramedullary disease or circulating plasma cells (66%), and advanced disease stage (37%). A suboptimal response (
Authors: C. Liberatore, A. Piciocchi, F. Accardi, E. Antonioli, A. Belotti, S. Bringhen, C. Conticello, D. Derudas, A. Furlan, S. Galimberti, L. Paris, M. Gentile, M. Krampera, M. Marcatti, G. Mele, R. Mina, M. Musso, F. Patriarca, A. Rago, E. Rossi, V. Sargentini, C. Skert, S. Soddu, D. Vincelli, L. Pavan, P. Tacchetti, S. Morè, Mt. Petrucci, N. Sgherza, F. Di Raimondo, M. Cavo
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7093123822
FWCI:
Cites:
Cited by:
Related to: